Avara Buys Sterile Manufacturing Facility from Pfizer

Published on: 

The acquisition adds sterile manufacturing capability to the CDMO’s services, which include API formulation and manufacturing.

Avara Pharmaceutical Services (Norwalk, CT), a contract development and manufacturing organization (CDMO), has signed an agreement with Pfizer to acquire Pfizer’s sterile manufacturing facility in Liscate, Italy, according to a company press release on August 8, 2017. The acquisition gives Avara five manufacturing sites in total.

In addition to the Liscate sterile manufacturing facility, Avara also has two API formulation and manufacturing facilities in Avlon, United Kingdom, and Shannon, Ireland, and two secondary manufacturing and packaging facilities in Norman, OK, United States, and Arecibo, Puerto Rico.

"This acquisition is an important component of our strategic plan and expands our services by adding sterile processing capability, which is in very high demand," said Timothy Tyson, Avara’s chairman and CEO, in the press release.

Avara provides both API formulation and manufacturing, along with secondary formulation, manufacturing, and packaging of small-molecule drugs, including highly potent compounds. The company has secondary manufacturing technologies including granulation, coating, blending, encapsulation, compression, and drying of tablets and capsules.


"As we celebrate another important milestone, we continue with great confidence to build a pharmaceutical services company with complementary offerings in key regions in this rapidly growing market. Each site has significant professional experience, state of the art capability and a long history of delivering high quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements in every major market around the world.  The people who are a part of the Avara team are the key to our long-term success," said Mr. Tyson in the press release. "We are focused on delivering on our commitments and earning the trust of every customer we deal with."

Source: Avara Pharmaceutical Services